The Rise of Blood-Brain-Barrier-Enabled Assets Infographic
This infographic Includes Insight Into:
- An inflection point for BBB-crossing technologies: Explore the delivery platforms shaping the next wave of CNS innovation.
- Rising disclosure of BBB data across modalities: A growing number of assets now report BBB penetration data, with notable activity across oligonucleotides, gene therapies, and antibodies.
- BBB-crossing strategies: Receptor-mediated transcytosis (RMT) is emerging as a leading approach for enabling BBB penetration. Here, we highlight where these strategies are being applied and how targets vary across CNS indications.
You May Also Be Interested In…
Learn More About Neuroscience
- The Most Comprehensive Way to Search the Neuroscience Drug Development Landscape: Unique search ontologies based on Neuroscience drug and trial characteristics
- Market Leading Approach to Neuroscience Preclinical & Clinical Data Curation: Manual curation of key Neuroscience research and development data points by Neuroscience research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Neuroscience company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!